stoxline Quote Chart Rank Option Currency Glossary
  
Aptevo Therapeutics Inc. (APVO)
0.581  0.251 (75.95%)    07-17 16:00
Open: 0.42
High: 0.6559
Volume: 315,145,826
  
Pre. Close: 0.3302
Low: 0.4
Market Cap: 4(M)
Technical analysis
2024-07-17 5:25:32 PM
Short term     
Mid term     
Targets 6-month :  1 1-year :  1.17
Resists First :  0.86 Second :  1
Pivot price 0.35
Supports First :  0.5 Second :  0.28
MAs MA(5) :  0.37 MA(20) :  0.4
MA(100) :  2.09 MA(250) :  9.21
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  35.4 D(3) :  19.6
RSI RSI(14): 56.2
52-week High :  50.15 Low :  0.28
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ APVO ] has closed above the upper band by 10.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 78% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 52 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.66 - 0.66 0.66 - 0.66
Low: 0.4 - 0.4 0.4 - 0.4
Close: 0.58 - 0.58 0.58 - 0.58
Company Description

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Headline News

Wed, 17 Jul 2024
Aptevo Therapeutics Inc ($APVO) Advances in Immuno-Oncology with Recent Offering and Warrant Amendments - Journal Transcript

Wed, 17 Jul 2024
StockNews.com Initiates Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World

Fri, 12 Jul 2024
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - American Banking and Market News

Fri, 28 Jun 2024
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules - StockTitan

Fri, 28 Jun 2024
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules - AccessWire

Tue, 16 Apr 2024
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 4 (M)
Shares Float 4 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 21 (K)
Shares Short P.Month 54 (K)
Stock Financials
EPS -94.41
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.06
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -66.8 %
Return on Equity (ttm) -186.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -6.77
Qtrly Earnings Growth 0 %
Operating Cash Flow -23 (M)
Levered Free Cash Flow -14 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0.06
Price to Sales 0
Price to Cash Flow -0.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android